Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

AusCann Cannabis Stocks

AusCann Cannabis Stock (ACNNF)

AusCann is a pharmaceutical company focusing on pre-clinical drug candidate development and production. They focus on cannabinoid drug candidates and are located in Australia.

Is AusCann Cannabis Stock (ACNNF) a strong BUY and HOLD?

ACNNF Fundamental Analysis

Profile

HQ: Perth, Western Australia
Founded: 2013
Symbol: ACNNF (OTC), AC8 (ASX)

FocusStrong 

Producing and selling medical cannabis to patients in Australia, and later the world. They are focused on creating cannabis treatments for pain, plus other conditions.  This is a $9 billion market in Australia alone. Many investors know of them from their relationship (now closed) with Canopy Growth. 

Size: Neutral

Market Cap: $31.6 mil
Enterprise Value: $17.94 mil
Number of Employees: 32

Markets: Neutral

Primary: Initially Australia (and Tasmania), where medical MJ is legal, but adult use is not (nor expected soon). Also Chile, through a partnership

Secondary: MA, CT, PA, and CA in the near future, Canada

Subsidiaries, Interests:
DayaCann (Chile), Yarra Glen Vineyards Holdings, ACN 096 717 458 Pty Ltd, Australian Commercial Wines Pty Ltd.
 

Operations: Neutral

Cultivation: None
Current production: Drug development focusing on their first product, for chronic pain, a dry powder 50:50 ratio of THC:CBD in a hard shell capsule formulation.

Distribution: Initial sales of their capsules are currently being ordered.
Direct sales: Yes

Store networks: Has an agreement with the leading Australian pharmacy API to distribute medical cannabis through nationwide pharmacy networks

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

Revenue (2019): $671,000
Shares Outstanding (diluted): 317 million
Return on Equity: -18.55%

Management: Neutral

CEO: Nick Woolf
CFO: Quentin Megson
Director: Max Johnston
Director: Bruce McHarrie
Director: Krista Bates

Old CEO Ido Kanyon stepped down in May. Much of the Board also turned over this year. The end of their relationship with Canopy late last year also shifted the directors. There has been a LOT of turnover for AusCann.

Branding: Neutral

Most of their drugs cover anti-convulsion, anti-inflammatory, anti-nausea, glaucoma, pain management, and appetite stimulation areas. They have not branded any of their drug candidates yet as none are approved.

Valuation: Weak

Current share price: $0.095
Price to Sales: 13,190
52 week low/high: $0.067-$0.25
EV/Revenue: 5,600
Price/Book: 1.22

Financing: Strong

AusCann has no debt but is burning cash fast, typical of most pharma companies undergoing drug development. Clinical trials are expensive, and they have over $34 million to pay for the next few (company net assets were reported at $34.37 million). They reported $7 million in losses last fiscal year. 

 

ACNNF Technical Analysis

Should I buy AusCann Cannabis Stock?

Is AusCann Cannabis Stock (ACNNF) a Buy?

Follow Stephen Goldman as he investigates the differences between common momentum-based indicators such as the MACD and KST (Know Sure Thing) while learning how to spot opportunities to buy and sell AusCann.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

52 week Range -
/

Bottom Line: Is AusCann Cannabis Stock (ACNNF) a Buy?

Recommendation: Weak

Is AusCann Cannabis Stock (ACNNF) a Buy?

AusCann is often referred to as having the lead position in the Australian cannabis industry. They used to have Canopy Growth as 10% investors but now Canopy has been replaced by local Australian Merchant Capital.

From a licensing perspective, they are ahead of other competitors in Australia. They can produce, sell import, and export. They may have a strong position if they can deliver on production and distribution. It’s a big unknown.

The company has reported only $671k in revenue for the year ending Dec 2019. This revenue was not based on sales as none of their drug candidates are approved. The drug furthest along is their 1:1 THC: CBD capsule for chronic pain indications. This would be a large market to enter (Pain drugs) but they are still a way away from sales for this drug.

Its price to sales ratio is an astronomical 13,000 and they EV/Revenue is 5,600. We don’t typically see values this high in our analyses (remember lower is better here).

They do have a partnership with Tasmanian Alkaloids Pty Ltd. to distribute medical cannabis in Tasmania. TasAlk produces 40% of the world’s alkaloid raw material and a partnership with DayaCann, the only licensed medicinal cannabis grower in Chile. These deals extend their reach internationally.

For all the reasons above, we rate this stock as Weak. Perhaps in a few more years, their drugs will be closer to approvals and they’ll be closer to revenue. Until then, expect dilution if you’re a shareholder.

For all the reasons above, we rate this stock as Weak but check out our other featured companies for many other winners in the cannabis and hemp industry.

Symbol Name Last Price Change % Change

Buy Alert: This Cannabis Stock Is Up 90% in November

Buy Alert: This Cannabis Stock Is Up 90% in November When stock prices spike, it makes you wonder whether it is a knee-jerk reaction to a market movement or announcement or some major news that you may have missed. November has been a particularly good month for...

Neptune Wellness: Will this Hemp Stock Gain Momentum in 2021?

Neptune Wellness: Will this Hemp Stock Gain Momentum in 2021? The health and wellness sector is a smart space to operate in as it's a $4.2 Trillion dollar industry. Hemp stocks with a health and wellness focus, such as, Neptune Wellness Solutions (NEPT) operate in...

Planet 13’s Q3: Out of this World

Planet 13 Announces Record Third Quarter 2020 Financial Results Q3 2020 Revenue of $22.8 million; Adjusted EBITDA of $6.2 million All figures are reported in United States dollars ($) unless otherwise indicated LAS VEGAS, NV / ACCESSWIRE / November 24, 2020 / Planet...

Decibel Announces Net Revenue Increase of 29%

Decibel Announces Net Revenue Increases of 29% from Prior Quarter, First Period of Positive Adjusted EBITDA and Results of Annual Meeting CALGARY, AB, Nov. 25, 2020 /CNW/ - Decibel Cannabis Company Inc. (the "Company" or "Decibel") (TSXV: DB) (OTCQB: DBCCF), a premium...

Cresco: Q3 Results Make it a Smart Value Buy

Cresco: Q3 Results Make it a Smart Value Buy Canadian cannabis stocks continue to dominate the headlines as several of these stocks are solid buys. Of course, there are great cannabis and hemp stocks in the U.S. as well. A few of these U.S.-based stocks are great...

3 Strong Buy and Hold Hemp Stocks for 2021

3 Strong Buy and Hold Hemp Stocks for 2021 With over 95% ballots reporting in most swing states, a Biden/Harris administration looks more likely with every passing day. While plenty of uncertainty over the legalization of marijuana in the U.S. remains, the industry...

Why is GW Pharmaceuticals a Strong Buy?

Why is GW Pharmaceuticals a Strong Buy? Cannabis stocks continue to soar after five states in the US legalized marijuana use on Friday, November 6. Stocks like Aurora Cannabis (NYSE: ACB) rose because the announcement acted as a lifeline to the much-troubled company....

What Cannabis & Hemp Stocks Benefit From Recent Legalization?

What Cannabis & Hemp Stocks Benefit From Recent Legalization? November 4, 2020, was a landmark day for the USA, and, surprisingly, it wasn’t due to this wild U.S. Presidential election. In fact, five new states in the country legalized marijuana. The cannabis...

CV Sciences: This Hemp Stock Will Surge Once There is Regulatory Clarity on CBD

CV Sciences: This Hemp Stock Will Surge Once There is Regulatory Clarity on CBD CV Sciences (CVSI) has been around for quite some time, and always competes fiercely. This is a company that once reaped the benefits of simply being a "cannabis stock" (remember the days...

When Will Canopy Growth Finally Turn a Profit?

When Will Canopy Growth Finally Turn a Profit? Canadian cannabis stocks have continued to underperform over this past year. Cannabis stocks like Canopy Growth Corporation (NYSE:CGC) have taken a beating and have seen massive hits on valuation. In fact, the stock is...